Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Stock Hits 52-Week High

NEW YORK (GenomeWeb News) – Shares of CombiMatrix closed at a 52-week high of $13.31 on Wednesday.
 
Over the past two weeks, shares of the Mukilteo, Wash.-based microarray manufacturer and molecular diagnostics firm have climbed around 20 percent. Year to date, the company’s stock is up nearly 80 percent.
 
Last week, CombiMatrix reported that its second-quarter revenues jumped 55 percent to $2.1 million, driven by diagnostic services revenue.
 
A year ago, the firm completed its split from former parent company Acacia Research as part of an effort to focus on the molecular diagnostics market.
 
 

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.